A Phase 2 interventional study of Crizotinib in Non Small Cell Lung Cancer, ROS1 Proto Oncogene and Crizotinib, sponsored by Pfizer. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 13 in phase 2, and was the 9th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 23 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 50th largest by enrollment of the 136 interventional ones that give a count, is one of 5 that started in 2013, is one of 45 in phase 2, and was the 57th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
2 of the studies testing crizotinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation (translocation or inversion) and confirmed negative for an ALK mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
Drug: Crizotinib
Also known as: Xalkori
Independent Radiology Reviewed Overall Objective Response (ORR)
Overall objective response (ORR) was defined as the number of patients with a best overall response of confirmed Complete Response or confirmed Partial Response according to RECIST v1.1 (as determined by Independent Radiology Review \[IRR\]), relative to the total population of response-evaluable participants. Per RECIST v1.1, CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Confirmed responses were those that persisted on repeat imaging at least 4 weeks after the initial documentation of response.
Time frame: Starting from the first dose study treatment until the first documented CR or PR (every 8 weeks then after 8 cycles at every 12 weeks in duration of 94.0 weeks)
IRR-Assessed Duration of Response (DR)
DR: time from first documentation of objective tumor response (CR or PR) to first documentation of objective progressive disease (PD) or to death due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, a) PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study), sum must also demonstrate an absolute increase of \>=5 mm, appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions; b) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); c) PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters.
Time frame: From first documentation of objective tumor response to first documentation of objective PD or death due to any cause, whichever occurred first (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
IRR-Assessed Time to Tumor Response (TTR)
TTR was defined as the time from the date of first dose to first documentation of objective tumor response (CR or PR), that was subsequently confirmed. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of first dose of crizotinib to first documentation of objective response was observed (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
IRR Assessed Disease Control Rate (DCR) at 8 Weeks
DCR at 8 weeks was defined as the percentage of participants with a confirmed CR, confirmed PR, or stable disease (SD) at 8 weeks, respectively, relative to the total population of response evaluable participants. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: At 8 weeks after the start of study treatment
IRR-Assessed Progression Free Survival (PFS)
PFS was defined as the time from the date of the first dose of crizotinib to first documentation of objective PD or to death on study due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered a sign of progression. Unequivocal progression of existing non-target lesions.
Time frame: From the date of first dose of crizotinib until the first documentation of objective PD or death (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
Overall Survival (OS)
OS was defined as the time from the date of the first dose of crizotinib to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.
Time frame: From date of the first dose of crizotinib until the date of death from any cause (up to 291.9 weeks)
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs
Treatment-emergent AEs :between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to crizotinib was assessed by the investigator. Treatment-related AE: any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE):an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death.
Time frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4
Laboratory values included hemoglobin increased, anemia, platelet count decreased, leukocytosis, white blood cell decreased, lymphocyte count increased, lymphocyte count decreased and neutrophil count decreased. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.
Time frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
Number of Participants With a Shift of Chemistry Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4
Laboratory values included blood bilirubin increased, alanine aminotransferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, hypoalbuminemia, hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hypophosphatemia, Creatinine increased, hyperuricemia, hypermagnesemia, hypomagnesemia, hyperglycemia and hypoglycemia. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.
Time frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores
The EORTC QLQ-C30 consists of 30 questions which are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global QOL scale; 3 symptom scales (fatigue, pain, nausea and vomiting scales); and 6 single items that assess the additional symptoms (dyspnea, appetite loss, sleep disturbance/insomnia, constipation, and diarrhea) and the perceived financial burden of treatment. All the scales and single-item scores ranged from 0 to 100, higher score is indicative of a higher response level (high score for a functional scale represents a high / healthy level of functioning; high score for the global health status / QoL represents a high QoL; a high score for a symptom scale / item represents a high level of symptomatology / problems).
Time frame: Baseline up to Cycle 60
Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores
The EORTC QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed specific symptoms (dyspnea, cough, hemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia). Scores on each scale and item ranged from 0 to 100, higher score is indicative of a higher response level (a high score for a symptom scale / item represents a high level of symptomatology / problems).
Time frame: Baseline up to Cycle 60
| Milestone | Crizotinib 250 mg |
|---|---|
| Started | 127 |
| Safety population | 127 |
| Response evaluable population | 127 |
| Patient reported outcome evaluable | 123 |
| Completed | 44 |
| Not completed | 83 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal of consent | 12 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Death | 65 |
Overall objective response (ORR) was defined as the number of patients with a best overall response of confirmed Complete Response or confirmed Partial Response according to RECIST v1.1 (as determined by Independent Radiology Review \[IRR\]), relative to the total population of response-evaluable participants. Per RECIST v1.1, CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Confirmed responses were those that persisted on repeat imaging at least 4 weeks after the initial documentation of response.
| Participants | Crizotinib 250 mg |
|---|---|
| Independent Radiology Reviewed Overall Objective Response (ORR) | 88 |
DR: time from first documentation of objective tumor response (CR or PR) to first documentation of objective progressive disease (PD) or to death due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, a) PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study), sum must also demonstrate an absolute increase of \>=5 mm, appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions; b) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); c) PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters.
| Months | Crizotinib 250 mg |
|---|---|
| IRR-Assessed Duration of Response (DR) | 19.7 (14.1 to NA) |
TTR was defined as the time from the date of first dose to first documentation of objective tumor response (CR or PR), that was subsequently confirmed. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Months | Crizotinib 250 mg |
|---|---|
| IRR-Assessed Time to Tumor Response (TTR) | 1.9 (1.6 to 15.8) |
DCR at 8 weeks was defined as the percentage of participants with a confirmed CR, confirmed PR, or stable disease (SD) at 8 weeks, respectively, relative to the total population of response evaluable participants. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of participants | Crizotinib 250 mg |
|---|---|
| IRR Assessed Disease Control Rate (DCR) at 8 Weeks | 88.2 (81.3 to 93.2) |
PFS was defined as the time from the date of the first dose of crizotinib to first documentation of objective PD or to death on study due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered a sign of progression. Unequivocal progression of existing non-target lesions.
| Months | Crizotinib 250 mg |
|---|---|
| IRR-Assessed Progression Free Survival (PFS) | 15.9 (12.9 to 24.0) |
OS was defined as the time from the date of the first dose of crizotinib to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.
| Months | Crizotinib 250 mg |
|---|---|
| Overall Survival (OS) | 44.2 (32.0 to NA) |
Treatment-emergent AEs :between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to crizotinib was assessed by the investigator. Treatment-related AE: any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE):an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death.
| Participants | Crizotinib 250 mg |
|---|---|
| Incidence of All-Causality Adverse Events | 127 |
| Incidence of All-Causality Serious Adverse Events | 46 |
| Incidence of Treatment Related Adverse Events | 124 |
| Incidence of Treatment Related Serious Adverse Events | 11 |
| Incidence of All-Causality Grade 3-4 Adverse Event | 68 |
| Incidence of Treatment Related Grade 3-4 Adverse Event | 41 |
Laboratory values included hemoglobin increased, anemia, platelet count decreased, leukocytosis, white blood cell decreased, lymphocyte count increased, lymphocyte count decreased and neutrophil count decreased. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.
| Participants | Crizotinib 250 mg |
|---|---|
| Hemoglobin Increased: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hemoglobin Increased: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hemoglobin Increased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Anemia: Baseline Grade 0 to Worst Grade 3 | 2 |
| Anemia: Baseline Grade 1 to Worst Grade 3 | 1 |
| Anemia: Baseline Grade 2 to Worst Grade 3 | 5 |
| Anemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Anemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Anemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Platelet Count Decreased: Baseline Grade 0 to Worst Grade 3 | 0 |
| Platelet Count Decreased: Baseline Grade 1 to Worst Grade 3 | 0 |
| Platelet Count Decreased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Platelet Count Decreased: Baseline Grade 0 to Worst Grade 4 | 0 |
| Platelet Count Decreased: Baseline Grade 1 to Worst Grade 4 | 0 |
| Platelet Count Decreased: Baseline Grade 2 to Worst Grade 4 | 0 |
| Leukocytosis: Baseline Grade 0 to Worst Grade 3 | 0 |
| Leukocytosis: Baseline Grade 0 to Worst Grade 4 | 0 |
| White Blood Cell Decreased: Baseline Grade 0 to Worst Grade 3 | 3 |
| White Blood Cell Decreased: Baseline Grade 1 to Worst Grade 3 | 1 |
| White Blood Cell Decreased: Baseline Grade 2 to Worst Grade 3 | 0 |
| White Blood Cell Decreased: Baseline Grade 0 to Worst Grade 4 | 0 |
| White Blood Cell Decreased: Baseline Grade 1 to Worst Grade 4 | 0 |
| White Blood Cell Decreased: Baseline Grade 2 to Worst Grade 4 | 0 |
| Lymphocyte Count Increased: Baseline Grade 0 to Worst Grade 3 | 0 |
| Lymphocyte Count Increased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Lymphocyte Count Decreased: Baseline Grade 0 to Worst Grade 3 | 4 |
| Lymphocyte Count Decreased: Baseline Grade 1 to Worst Grade 3 | 0 |
| Lymphocyte Count Decreased: Baseline Grade 2 to Worst Grade 3 | 2 |
| Lymphocyte Count Decreased: Baseline Grade 0 to Worst Grade 4 | 0 |
| Lymphocyte Count Decreased: Baseline Grade 1 to Worst Grade 4 | 0 |
| Lymphocyte Count Decreased: Baseline Grade 2 to Worst Grade 4 | 0 |
| Neutrophil Count Decreased: Baseline Grade 0 to Worst Grade 3 | 7 |
| Neutrophil Count Decreased: Baseline Grade 1 to Worst Grade 3 | 1 |
| Neutrophil Count Decreased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Neutrophil Count Decreased: Baseline Grade 0 to Worst Grade 4 | 4 |
| Neutrophil Count Decreased: Baseline Grade 1 to Worst Grade 4 | 0 |
| Neutrophil Count Decreased: Baseline Grade 2 to Worst Grade 4 | 0 |
Laboratory values included blood bilirubin increased, alanine aminotransferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, hypoalbuminemia, hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hypophosphatemia, Creatinine increased, hyperuricemia, hypermagnesemia, hypomagnesemia, hyperglycemia and hypoglycemia. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.
| Participants | Crizotinib 250 mg |
|---|---|
| Blood Bilirubin Increased: Baseline Grade 0 to Worst Grade 3 | 1 |
| Blood Bilirubin Increased: Baseline Grade 1 to Worst Grade 3 | 0 |
| Blood Bilirubin Increased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Blood Bilirubin Increased: Baseline Grade 0 to Worst Grade 4 | 0 |
| Blood Bilirubin Increased: Baseline Grade 1 to Worst Grade 4 | 0 |
| Blood Bilirubin Increased: Baseline Grade 2 to Worst Grade 4 | 0 |
| Alanine Aminotransferase Increased: Baseline Grade 0 to Worst Grade 3 | 4 |
| Alanine Aminotransferase Increased: Baseline Grade 1 to Worst Grade 3 | 1 |
| Alanine Aminotransferase Increased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Alanine Aminotransferase Increased: Baseline Grade 0 to Worst Grade 4 | 4 |
| Alanine Aminotransferase Increased: Baseline Grade 1 to Worst Grade 4 | 0 |
| Alanine Aminotransferase Increased: Baseline Grade 2 to Worst Grade 4 | 0 |
| Aspartate Aminotransferase Increased : Baseline Grade 0 to Worst Grade 3 | 2 |
| Aspartate Aminotransferase Increased : Baseline Grade 1 to Worst Grade 3 | 0 |
| Aspartate Aminotransferase Increased : Baseline Grade 2 to Worst Grade 3 | 0 |
| Aspartate Aminotransferase Increased : Baseline Grade 0 to Worst Grade 4 | 4 |
| Aspartate Aminotransferase Increased : Baseline Grade 1 to Worst Grade 4 | 0 |
| Aspartate Aminotransferase Increased : Baseline Grade 2 to Worst Grade 4 | 0 |
| Alkaline Phosphatase Increased : Baseline Grade 0 to Worst Grade 3 | 0 |
| Alkaline Phosphatase Increased : Baseline Grade 1 to Worst Grade 3 | 0 |
| Alkaline Phosphatase Increased : Baseline Grade 2 to Worst Grade 3 | 0 |
| Alkaline Phosphatase Increased : Baseline Grade 0 to Worst Grade 4 | 0 |
| Alkaline Phosphatase Increased : Baseline Grade 1 to Worst Grade 4 | 0 |
| Alkaline Phosphatase Increased : Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypoalbuminemia: Baseline Grade 0 to Worst Grade 3 | 1 |
| Hypoalbuminemia: Baseline Grade 1 to Worst Grade 3 | 1 |
| Hypoalbuminemia: Baseline Grade 2 to Worst Grade 3 | 1 |
| Hypoalbuminemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypoalbuminemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypoalbuminemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypernatremia: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hypernatremia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypernatremia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hypernatremia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypernatremia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypernatremia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hyponatremia: Baseline Grade 0 to Worst Grade 3 | 8 |
| Hyponatremia: Baseline Grade 1 to Worst Grade 3 | 4 |
| Hyponatremia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hyponatremia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hyperkalemia: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hyperkalemia: Baseline Grade 1 to Worst Grade 3 | 1 |
| Hyperkalemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hyperkalemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hyperkalemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hyperkalemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypokalemia: Baseline Grade 0 to Worst Grade 3 | 5 |
| Hypokalemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypokalemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hypokalemia: Baseline Grade 0 to Worst Grade 4 | 1 |
| Hypokalemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypokalemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypercalcemia: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hypercalcemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypercalcemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hypercalcemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypercalcemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypercalcemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypocalcemia: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hypocalcemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypocalcemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hypocalcemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypocalcemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypocalcemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypophosphatemia: Baseline Grade 0 to Worst Grade 3 | 11 |
| Hypophosphatemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypophosphatemia: Baseline Grade 2 to Worst Grade 3 | 1 |
| Hypophosphatemia: Baseline Grade 0 to Worst Grade 4 | 1 |
| Hypophosphatemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypophosphatemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Creatinine Increased: Baseline Grade 0 to Worst Grade 3 | 1 |
| Creatinine Increased: Baseline Grade 1 to Worst Grade 3 | 0 |
| Creatinine Increased: Baseline Grade 2 to Worst Grade 3 | 0 |
| Creatinine Increased: Baseline Grade 0 to Worst Grade 4 | 0 |
| Creatinine Increased: Baseline Grade 1 to Worst Grade 4 | 0 |
| Creatinine Increased: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hyperuricemia: Baseline Grade 0 to Worst Grade 3 | 33 |
| Hyperuricemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hyperuricemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hyperuricemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypermagnesemia: Baseline Grade 0 to Worst Grade 3 | 2 |
| Hypermagnesemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypermagnesemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypermagnesemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypomagnesemia: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hypomagnesemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypomagnesemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hypomagnesemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypomagnesemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypomagnesemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hyperglycemia: Baseline Grade 0 to Worst Grade 3 | 1 |
| Hyperglycemia: Baseline Grade 1 to Worst Grade 3 | 1 |
| Hyperglycemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hyperglycemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hyperglycemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hyperglycemia: Baseline Grade 2 to Worst Grade 4 | 0 |
| Hypoglycemia: Baseline Grade 0 to Worst Grade 3 | 0 |
| Hypoglycemia: Baseline Grade 1 to Worst Grade 3 | 0 |
| Hypoglycemia: Baseline Grade 2 to Worst Grade 3 | 0 |
| Hypoglycemia: Baseline Grade 0 to Worst Grade 4 | 0 |
| Hypoglycemia: Baseline Grade 1 to Worst Grade 4 | 0 |
| Hypoglycemia: Baseline Grade 2 to Worst Grade 4 | 0 |
The EORTC QLQ-C30 consists of 30 questions which are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global QOL scale; 3 symptom scales (fatigue, pain, nausea and vomiting scales); and 6 single items that assess the additional symptoms (dyspnea, appetite loss, sleep disturbance/insomnia, constipation, and diarrhea) and the perceived financial burden of treatment. All the scales and single-item scores ranged from 0 to 100, higher score is indicative of a higher response level (high score for a functional scale represents a high / healthy level of functioning; high score for the global health status / QoL represents a high QoL; a high score for a symptom scale / item represents a high level of symptomatology / problems).
| Units on a scale | Crizotinib 250 mg |
|---|---|
| Global Health Status | 11.85 ± 20.844 |
| Physical Functioning | 3.08 ± 11.964 |
| Role Functioning | -0.65 ± 17.945 |
| Emotional Functioning | 10.77 ± 18.146 |
| Cognitive Functioning | 3.20 ± 14.159 |
| Social Functioning | 5.13 ± 20.961 |
| Fatigue | -12.30 ± 20.156 |
| Nausea and Vomiting | 0.64 ± 14.517 |
| Pain | -12.18 ± 16.027 |
| Dyspnea | -6.41 ± 21.124 |
| Insomnia | -11.53 ± 16.161 |
| Appetite loss | -14.10 ± 23.428 |
| Constipation | 10.26 ± 27.920 |
| Diarrhoea | 1.28 ± 19.937 |
| Financial difficulties | -21.80 ± 28.199 |
The EORTC QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed specific symptoms (dyspnea, cough, hemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia). Scores on each scale and item ranged from 0 to 100, higher score is indicative of a higher response level (a high score for a symptom scale / item represents a high level of symptomatology / problems).
| Units on a scale | Crizotinib 250 mg |
|---|---|
| Dyspnea | -4.74 ± 14.791 |
| Coughing | -12.82 ± 29.936 |
| Hemoptysis | -5.12 ± 12.253 |
| Sore mouth | -1.28 ± 14.844 |
| Dysphagia | 0.00 ± 16.314 |
| Peripheral neuropathy | 3.85 ± 19.611 |
| Alopecia | -2.57 ± 20.910 |
| Pain in chest | -12.82 ± 21.236 |
| Pain in arm or shoulder | -15.37 ± 23.536 |
| Pain in other parts | -7.68 ± 21.718 |
Collected over Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crizotinib 250 mg | 65/127 (51.2%) | 46/127 (36.2%) | 127/127 (100%) |
| Event | Crizotinib 250 mg |
|---|---|
| PneumoniaInfections and infestations | 10/127 |
| Disease ProgressionGeneral disorders | 7/127 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/127 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/127 |
| Hepatic function abnormalHepatobiliary disorders | 2/127 |
| Alanine aminotransferase increasedInvestigations | 2/127 |
| Renal cystRenal and urinary disorders | 2/127 |
| Deep vein thrombosisVascular disorders | 2/127 |
| Acute myocardial infarctionCardiac disorders | 1/127 |
| Abdominal painGastrointestinal disorders | 1/127 |
| Event | Crizotinib 250 mg |
|---|---|
| Alanine aminotransferase increasedInvestigations | 72/127 |
| Aspartate aminotransferase increasedInvestigations | 67/127 |
| DiarrhoeaGastrointestinal disorders | 62/127 |
| NauseaGastrointestinal disorders | 58/127 |
| VomitingGastrointestinal disorders | 50/127 |
| ConstipationGastrointestinal disorders | 49/127 |
| Oedema peripheralGeneral disorders | 39/127 |
| Neutrophil count decreasedInvestigations | 37/127 |
| CoughRespiratory, thoracic and mediastinal disorders | 35/127 |
| White blood cell count decreasedInvestigations | 30/127 |
The Safety Population contains all enrolled participants who received at least one dose of study medication.
| Age, Continuous(Years) | Crizotinib 250 mg |
|---|---|
| Mean | 52.48 ± 12.136 |
| Sex: Female, Male(Participants) | Crizotinib 250 mg |
|---|---|
| Female | 73 |
| Male | 54 |
| Race/Ethnicity, Customized(Participants) | Crizotinib 250 mg |
|---|---|
| Asian | 127 |
| Region of Enrollment(Participants) | Crizotinib 250 mg |
|---|---|
| Asia — China | 74 |
| Asia — Japan | 26 |
| Asia — Korea | 12 |
| Asia — Taiwan | 15 |
Ran from Sep 2013 to primary completion in Jul 2015, 22 months.
Results were first posted in Aug 2016, 1 year after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib
Carcinoma, Non-Small-Cell Lung →